Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Abbott Laboratories posted solid Q2 results, with 13% reported growth and 4.8% organic growth, showing Exact Sciences integration is proceeding better than expected. Adjusted EPS of $1.31 beat forecasts, and improved earnings guidance alongside limited margin contraction boosted investor sentiment and the share price. Abbott maintains strong capital returns as a Dividend King with a 2.8% yield, supported by broad institutional buying and firming analyst price targets.

Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.

Looking forward, profitability metrics have improved, leading to improved guidance, strengthened market sentiment, and a robust rebound in the share price. The share price rebound is an operative factor in the second half of 2026. Abbott’s market was overly depressed, given its historical value and capacity for capital returns, signaling a buying opportunity for investors. The post-release surge not only confirms support at the existing lows but is also backed by MACD and stochastic signals, suggesting a full reversal is in play. The market completely misjudged the Exact Sciences deal, focusing too intently on near-term margin pressure and execution risk, rather than the long-term commercial impact on revenue, margins, and earnings.

Abbott Laboratories' Q2 report is solid, with reported growth of 13% and organic growth of 4.8%. Strength was underpinned by Exact Sciences and the 42.3% increase in Diagnostic services it brought, aided by an 8.4% increase in Established Pharmaceuticals and a 7.9% increase in Medical Devices. Nutrition, among the smaller segments, declined by 3.1%. Regionally, strengths were seen domestically and abroad.

Margin news was the catalyzing factor. The company’s margins contracted but less than expected, leaving gross margin, operating and net income above analysts' forecasts. The critical takeaway is that $1.31 in adjusted earnings per share (EPS) outperformed by 235 basis points and is sufficient to sustain financial health while reinvesting and returning capital to shareholders.

Guidance is another catalyzing factor for back-half trading. The company maintained its forecast for organic revenue growth but improved the outlook for earnings, lifting the midpoint and narrowing the range for full-year results. With momentum building and results forecasted to accelerate in the back half, the guidance is likely to be cautious, setting the stage for additional catalysts by year’s end.

Abbott’s capital return was never in any real danger, but the threat of margin compression and cash flow impairment was sufficient to weigh on sentiment. The takeaway from the Q2 release, however, is that concerns are misplaced. Capital returns will continue to flow, including the dividend and share buybacks, and buybacks may accelerate. As it stands, Abbott is a Dividend King with nearly 55 consecutive increases to its credit, a manageable 70% payout ratio, and buybacks to offset the impact of annual increases and build shareholder leverage. The dividend yield is more than attractive, as of mid-July...